3D Printing Takes Flight, Dementia Data Delivers, and Biotech Meets a Tough Crowd

A push into 3D-printed spacecraft hardware and encouraging dementia biomarker data sparked sharp rallies.

Elsewhere, mixed trial results and sector rotation made it a tougher day for parts of biotech and consumer names.

U.S. defense spending just passed $1 trillion, driving massive demand for drones, hypersonics, and next-gen aerospace.

At the center is titanium, essential for fighter jets, missiles, and long-range UAVs — yet 91% of it is imported.

One new discovery in Canada is turning heads with a massive titanium-vanadium system near shipping, power, and skilled labor.

Recent surveys returned magnetometer readings so strong they maxed out the equipment, showing rare scale and grade.

This could be North America’s most strategic new titanium source, and it’s still flying under the radar.

Read the full story here.

Equities moved higher, led by gains in banks and oil producers after crude prices climbed on expectations that U.S. involvement in Venezuela could reshape future supply dynamics.

LifeMD (NASDAQ: LFMD) has made a defining move by adding Novo Nordisk’s Wegovy pill to its telehealth platform, pushing the company straight into the center of modern obesity care.

The Wegovy pill removes one of the biggest barriers in weight management, injections.

By offering an FDA-approved oral GLP-1 through virtual care, LifeMD lowers friction and widens access in a way that immediately changes how patients enter treatment.

Pills Open the Front Door Wide

Oral GLP-1s make it easier for people to start therapy earlier, before hesitation or logistics slow things down. That expands the patient pool and reshapes demand.

When starting treatment feels simpler, you see adoption rise faster. This is where LifeMD captures patients before they drift toward unstructured or short-term solutions.

Recurring Care Becomes the Engine

Obesity treatment does not end with a prescription. It requires monitoring, adjustments, and long-term support, which fits perfectly into LifeMD’s virtual care model.

Instead of one-off visits, the platform builds ongoing relationships.

That creates durable engagement, predictable care cycles, and stronger outcomes, and you start to see why this move matters beyond headlines.

Credibility Beats Hype Platforms

LifeMD is aligning with branded, FDA-approved therapy backed by Novo Nordisk, not gray-market shortcuts. That distinction matters as competition intensifies.

For patients and partners, trust becomes the differentiator.

LifeMD is not just offering access; it is shaping how obesity care is delivered, and if you are watching closely, this is telehealth stepping into its clinical era.

JPMorgan Chase (NYSE: JPM) has launched a new Special Advisory Services unit, and this is not another boutique add-on.

It is a structural change in how the bank plans to serve its most powerful clients as disruption becomes constant and decisions get harder.

The unit is designed for a tight circle of long-standing, top-tier corporate relationships.

Its focus stretches well beyond deals into areas now shaping boardroom strategy, artificial intelligence, cybersecurity, digital assets, geopolitics, healthcare, supply chains, and sustainability.

When Advice Moves Ahead of Transactions

Corporate demand is changing fast. Instead of calling ten advisers after a problem shows up, companies want fewer partners who help them see around corners.

This unit puts JPMorgan inside strategic conversations earlier than ever.

Long before a deal, listing, or restructuring appears, the bank is already advising on direction, risk, and timing, and you can see how that rewires influence.

Locking the Relationship Before the Deal

The unit will support companies preparing for IPOs, pursuing transformational moves, or consolidating banking relationships.

That gives JPMorgan deeper access and more durable ties when choices still feel fluid.

For competitors, the bar just moved. Advisory is no longer just execution; it is interpretation and foresight.

JPMorgan is betting that trust built early wins later, and if you are watching closely, this is the bank positioning itself as the place clients turn when the path forward is unclear, not just when paperwork begins.

The man who predicted the 2008 crash and 2020 says today's soaring markets are NOT a bubble - they're something far stranger and more dangerous.

He says it's about to change everything you know about money.

Full story here. 

Microsoft (NASDAQ: MSFT) has quietly made one of its smartest data platform moves in years by acquiring Osmos, an AI startup built to automate the most painful part of enterprise analytics, data preparation.

This is not about adding another AI button. It is about removing the thing that slows everything else down.

Across enterprises, teams still burn massive time cleaning, stitching, and reshaping data before any insight happens.

That friction limits how fast AI rolls out and how much value cloud investments actually deliver.

If you have ever waited weeks for clean data before analysis even starts, you already know the problem.

Microsoft Attacks the Mess First

Osmos uses agentic AI to turn raw data into analytics-ready formats automatically.

By pulling this directly into Microsoft Fabric, automation moves upstream, closer to where data is created.

That shift matters because speed compounds.

When prep fades into the background, analytics moves at business pace instead of engineering pace, and suddenly you are asking better questions sooner.

Fabric Becomes Hard to Walk Away From

Embedding automated prep inside Fabric and OneLake quietly raises switching costs. Customers are not just using tools anymore; they are plugging into a flow that works end-to-end.

This acquisition makes the direction obvious.

Data engineering disappears, analytics accelerates, and Microsoft keeps tightening its grip on how enterprise AI is actually delivered

👉 Click here to get our closing report to your cell for free!

Momentus Inc [MNTS] $8.82 (+53.66%)

Momentus rose after unveiling a 3D-printed fuel tank to be flight-tested on its Vigoride-7 mission, highlighting the potential for faster, lower-cost spacecraft production using additive manufacturing.

Intelligent Bio Solutions Inc [INBS] $11.00 (+39.42%)

Intelligent Bio Solutions jumped after announcing a strategic manufacturing partnership expected to cut production costs by more than 40% and expand capacity for its fingerprint drug-screening reader.

Passage Bio Inc [PASG] $16.11 (+37.81%)

Passage Bio gained after reporting encouraging Phase 1/2 data showing sustained increases in progranulin and reductions in disease-related biomarkers in frontotemporal dementia patients treated with PBFT02.

Zenas Biopharma Inc [ZBIO] $16.61 (-51.86%)

Zenas BioPharma plunged after its drug obexelimab cut flare-up risk by 56% in IgG4-related disease, falling short of analyst expectations and trailing a rival therapy’s stronger results.

Capricor Therapeutics Inc [CAPR] $24.81 (-12.36%)

Capricor declined amid a sector-wide pullback in biotech valuations, as money flowed into energy plays after the U.S. arrested Venezuela’s Nicolás Maduro.

Sleep Number Corp [SNBR] $7.89 (-8.15%)

Sleep Number fell after the shutdown of a regional mattress retailer highlighted intensifying competition from large brands and online sellers across the mattress industry.

They mocked your values and expected everyday Americans to stay financially exposed.

Now the dollar faces pressure, global conflicts threaten stability, and inflation quietly eats away at savings.

Doing nothing is exactly what powerful interests are counting on as uncertainty grows.

This Patriot’s Tax Shield explains how real, physical gold can help defend wealth during political and economic disruption.

A free Wealth Protection Guide reveals how Trump’s agenda could impact gold and why timing matters now.

Click here to get the FREE Wealth Protection Guide now.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.